Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshie Morimoto

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
JTO Clinical and Research Reports|September 9, 2022
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With <i>EGFR</i>-Mutant NSCLCKenji Morimoto, Ryo Sawada, Tadaaki Yamada, et al.
Oncoimmunology|July 22, 2021
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.
Journal of Cancer Research and Clinical Oncology|September 12, 2021
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 9, 2021
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancerKenji Morimoto, Tadaaki Yamada, Takashi Yokoi, et al.
Medical Oncology (Northwood, London, England)|November 11, 2020
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patientsKenji Morimoto, Tadaaki Yamada, Ryota Nakamura, et al.
Journal of Cancer Research and Clinical Oncology|November 26, 2021
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patientsRyota Nakamura, Tadaaki Yamada, Kenji Morimoto, et al.
JTO Clinical and Research Reports|November 28, 2022
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical TrialMakoto Hibino, Osamu Hiranuma, Yoshizumi Takemura, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 7, 2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)Kenji Morimoto, Junji Uchino, Makoto Hibino, et al.
Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated <i>EGFR</i>-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
NPJ Precision Oncology|January 19, 2022
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal featuresKeiko Tanimura, Tadaaki Yamada, Koutaroh Okada, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
JTO Clinical and Research Reports|September 9, 2022
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With <i>EGFR</i>-Mutant NSCLCKenji Morimoto, Ryo Sawada, Tadaaki Yamada, et al.
Oncoimmunology|July 22, 2021
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.
Journal of Cancer Research and Clinical Oncology|September 12, 2021
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 9, 2021
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancerKenji Morimoto, Tadaaki Yamada, Takashi Yokoi, et al.
Medical Oncology (Northwood, London, England)|November 11, 2020
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patientsKenji Morimoto, Tadaaki Yamada, Ryota Nakamura, et al.
Journal of Cancer Research and Clinical Oncology|November 26, 2021
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patientsRyota Nakamura, Tadaaki Yamada, Kenji Morimoto, et al.
JTO Clinical and Research Reports|November 28, 2022
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical TrialMakoto Hibino, Osamu Hiranuma, Yoshizumi Takemura, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 7, 2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)Kenji Morimoto, Junji Uchino, Makoto Hibino, et al.
Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated <i>EGFR</i>-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
NPJ Precision Oncology|January 19, 2022
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal featuresKeiko Tanimura, Tadaaki Yamada, Koutaroh Okada, et al.
Pageof 4